Belmont Capital’s GSK GSK Stock Holding History

Belmont Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,992	Closed	-$115K	–	186
2024 Q2	$115K	Hold	2,992	–	–	0.02%	147
2024 Q1	$128K	Hold	2,992	–	–	0.04%	108
2023 Q4	$111K	Buy	+2,992	New	+$107K	0.05%	94

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belmont Capital's GSK Position: Q3 2024 in Review

Belmont Capital sold out of GSK (GSK) in Q3 2024, closing a stake of 2,992 shares — an estimated $115K sold.

Belmont Capital first reported a position in GSK in Q4 2023 and held it in 3 quarters. The position peaked at $128K in Q1 2024. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Belmont Capital reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Belmont Capital sold 2,992 GSK shares in Q3 2024, an estimated $115K.
Belmont Capital first reported a position in GSK in Q4 2023 and held it in 3 quarters.
Belmont Capital's GSK position peaked at $128K in Q1 2024.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Belmont Capital's 13F filing for Q3 2024, filed 7 Nov 2024.